세계의 종양학 동반 진단 시장 (2023-2030) : 제품 및 서비스별, 기술별 (IHC, NGS), 질환별 (유방암, 백혈병), 용도별, 지역별

■ 영문 제목 : Oncology Companion Diagnostic Market Size, Share & Trends Analysis Report By Product & Service, By Technology (IHC, NGS), By Disease Type (Breast Cancer, Leukemia), By End Use, By Region, And Segment Forecasts, 2023 - 2030

Grand View Research 회사가 출판한 조사자료로, 코드는 GRV23NOV178 입니다.■ 상품코드 : GRV23NOV178
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 9월
■ 페이지수 : 183
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 임상 진단
■ 판매가격 / 옵션 (부가세 10% 별도)
Single User (1인 열람용)USD5,950 ⇒환산₩8,032,500견적의뢰/주문/질문
Multi User (5인 열람용)USD6,950 ⇒환산₩9,382,500견적의뢰/주문/질문
Global/corporate License (기업 열람용)USD8,950 ⇒환산₩12,082,500견적의뢰/구입/질문
가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
글로벌 종양학 동반 진단 시장의 성장과 동향
Grand View Research사의 최신 보고서에 따르면, 세계의 종양학 동반 진단 시장 규모는 2023년부터 2030년까지 연평균 12. 9%의 성장률로 확대되어 2030년에는 82억 달러에 달할 것으로 예상됩니다. 동반 진단을 통해 중요한 유전체 정보에 대한 접근이 확대되면 정보에 입각한 의사결정을 내릴 수 있고, 환자 맞춤형 치료법을 설계할 수 있어 종합적인 유전체 검사 및 종양학 동반 진단에 대한 수요가 증가할 것으로 예상됩니다.

글리벡(글리벡), 허셉틴(허셉틴) 등 처방 전 동반 진단(CDx) 검사가 필요한 약물의 출시로 종양학 동반 진단의 수익이 증가하고 있습니다. 이러한 성장은 임상시험 중인 다수의 CDx 관련 암 치료제로 인해 향후에도 지속될 것으로 예상되며, CDx는 치료를 위한 독점적 또는 포괄적인 검사로서의 기능 외에도 임상시험 참여자 선정에 중요한 역할을 할 것으로 보입니다. 환자가 바이오마커의 표적을 가지고 있다면 신약 후보물질이 더 높은 반응률을 보일 가능성이 높아지기 때문입니다.

CDx 사용과 관련된 경제적 인센티브는 의약품 개발자들이 의약품과 진단 테스트를 결합하도록 유도하고 있습니다. 하지만 진단업체들은 한편으로는 지불자/의료 제공자, 다른 한편으로는 제약업체들의 상반된 요구에 직면해 있습니다. 또한, 규제 기관은 진단과 의약품의 개발 일정을 일치시키기 위해 엄격한 정책을 시행하고 있습니다. 따라서 진단제 제조업체는 단일 진단제와 특정 의약품의 매칭에 초점을 맞추기보다는 CDx 개발의 범위를 넓혀야 할 것으로 예상됩니다.

종양학 동반 진단 시장 보고서 하이라이트

- CDx 검사의 채택률과 사용률이 증가함에 따라 제품 분야는 2022년 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.

- CDx의 승인률이 크게 증가하고 의약품과 CDx의 공동 개발에 대한 투자가 증가함에 따라 제품 부문의 수익이 증가할 것으로 예상됩니다.

- CDx 검사에 필요한 배지, 완충액, 시약 및 기타 소모품은 자주 사용 및 구매하기 때문에 소모품이 제품 부문의 주요 점유율을 차지합니다.

- 면역조직화학(IHC)은 비용 및 시간 효율성, 작은 종양 유형에 대한 IHC 기술의 적합성, 일상적인 종양 CDx에서 IHC의 높은 채택률, IHC와 관련된 낮은 기술 요구 사항 등 IHC 기술이 제공하는 장점으로 인해 기술 부문의 대부분을 차지하고 있습니다.

- EGFR pharmDx 키트, ER/PR pharmDx 키트, HercepTest 키트, PD-L1 IHC 28-8 pharmDx, VENTANA PD-L1 (SP142) Assay, VENTANA ALK (D5F3) CDx Assay, VENTANA ALK IHC assay 등 FDA가 승인한 다수의 IHC 기반 CDx assay가 존재한다는 점도 IHC 부문 내 매출 증가를 가져올 것으로 예상됩니다.

- 비소세포폐암(NSCLC) 부문은 2022년 시장을 지배할 것으로 예상되며, 예측 기간 동안에도 그 우위를 유지할 것으로 보입니다.

- 비소세포폐암은 폐암의 하위 유형으로 폐암의 약 80%를 차지합니다. 미국암협회(ACS)가 발표한 자료에 따르면, 2020년 미국에서 약 228,820명의 폐암 환자가 새로 진단될 것으로 예상됩니다.

- 유방암과 백혈병 분야는 암 환자 수 증가로 인해 큰 폭의 성장이 예상됩니다.

- 병원 부문은 2022년 시장에서 가장 큰 점유율을 차지할 것으로 예상되며, 병원 내 암 진단 검사 건수 증가로 인해 상당한 성장률을 보일 것으로 예상됩니다.

- 2022년 북미 지역이 시장을 주도할 것으로 예상되는데, 이 지역에는 다수의 플레이어가 존재하고 암 치료에서 FDA 승인을 받은 CDx 솔루션이 다수 존재하기 때문입니다.

- 기술 발전과 경제 상황의 개선으로 아시아 태평양 지역이 가장 빠른 성장률로 시장을 주도할 것으로 예상됩니다.

- 아시아 국가들에서 유전자 바이오마커 모니터링 및 발견에 적극적으로 참여하는 커뮤니티가 존재한다는 점이 시장에 긍정적인 영향을 미칠 것으로 예상됩니다.
■ 보고서 개요

Chapter 1. 조사 방법 및 범위
Chapter 2. 개요
Chapter 3. 시장 변동, 동향, 범위
Chapter 4. 세계의 종양학 동반 진단 시장 : 제품 및 서비스별 예측 및 동향 분석
Chapter 5. 세계의 종양학 동반 진단 시장 : 기술별 예측 및 동향 분석
Chapter 6. 세계의 종양학 동반 진단 시장 : 질병 유형별 예측 및 동향 분석
Chapter 7. 세계의 종양학 동반 진단 시장 : 최종 용도별 예측 및 동향 분석
Chapter 8. 세계의 종양학 동반 진단 시장 : 지역별 예측 및 동향 분석
Chapter 9. 경쟁 현황

■ 보고서 목차

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product & Service
1.1.2. Technology
1.1.3. Disease type
1.1.4. End use
1.1.5. Regional scope
1.1.6. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product & service outlook
2.2.2. Technology outlook
2.2.3. Disease type outlook
2.2.4. End use outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. Oncology Companion Diagnostic Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Oncology Companion Diagnostic Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Oncology Companion Diagnostic: Product and Services estimates & Trend Analysis
4.1. Oncology Companion Diagnostic Market, By Product & Services Key Takeaways
4.2. Oncology Companion Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Product
4.3.1. Product and services market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2. Instrument
4.3.2.1. Instrument market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3. Consumable
4.3.3.1. Consumable market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.4. Software
4.3.4.1. Software market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Service
4.4.1. Service market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Oncology Companion Diagnostic: Technology Estimates & Trend Analysis
5.1. Oncology Companion Diagnostic Market, By Technology Key Takeaways
5.2. Oncology Companion Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Polymerase Chain Reaction (PCR)
5.3.1. Polymerase chain reaction (PCR) market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Next-Generation Sequencing (NGS)
5.4.1. Next-generation sequencing (NGS) market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Immunohistochemistry (IHC)
5.5.1. Immunohistochemistry (IHC) market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. In Situ Hybridization (ISH)/ Fluorescence in Situ Hybridization (FISH)
5.6.1. In itu Hybridization (ISH)/ Fluorescence in Situ Hybridization (FISH) market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Other Technologies
5.7.1. Other technologies market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Oncology Companion Diagnostic: By Disease Type Estimates & Trend Analysis
6.1. Oncology Companion Diagnostic Market, By Disease Type Key Takeaways
6.2. Oncology Companion Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Breast Cancer
6.3.1. Breast cancer market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Non-Small Cell Lung Cancer
6.4.1. Non-small cell lung cancer market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Colorectal Cancer
6.5.1. Colorectal cancer market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Leukemia
6.6.1. Leukemia market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Melanoma
6.7.1. Melanoma market estimates and forecasts, 2018 to 2030 (USD Million)
6.8. Prostate Cancer
6.8.1. Prostate cancer market estimates and forecasts, 2018 to 2030 (USD Million)
6.9. Others
6.9.1. Other market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Oncology Companion Diagnostic: By End Use Estimates & Trend Analysis
7.1. Oncology Companion Diagnostic Market, By End Use Key Takeaways
7.2. Oncology Companion Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
7.3. Hospital
7.3.1. Hospital market estimates and forecasts, 2018 to 2030 (USD Million)
7.4. Pathology/Diagnostic Laboratory
7.4.1. Pathology/Diagnostic laboratory market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Academic Medical Center
7.5.1. Academic medical center market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Diagnostic Market: Regional Estimates & Trend Analysis
8.1. Regional Outlook
8.2. Oncology Companion Diagnostic Market by Region: Key Takeaways
8.3. North America
8.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.3.2. U.S.
8.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.3.3. Canada
8.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.2. Germany
8.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.3. France
8.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.4. Italy
8.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.5. Spain
8.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.6. Sweden
8.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.7. Norway
8.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.8. Denmark
8.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5.2. China
8.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5.3. India
8.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5.4. Australia
8.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5.5. Thailand
8.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5.6. South Korea
8.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.6.2. Mexico
8.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.6.3. Argentina
8.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.7. MEA
8.7.1. Saudi Arabia
8.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.7.2. South Africa
8.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.7.3. UAE
8.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.7.4. Kuwait
8.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.2.1. Agilent Technologies, Inc.
9.2.1.1. Company overview
9.2.1.2. Financial performance
9.2.1.3. Product benchmarking
9.2.1.4. Strategic initiatives
9.2.2. Illumina, Inc.
9.2.2.1. Company overview
9.2.2.2. Financial performance
9.2.2.3. Product benchmarking
9.2.2.4. Strategic initiatives
9.2.3. QIAGEN N.V.
9.2.3.1. Company overview
9.2.3.2. Financial performance
9.2.3.3. Product benchmarking
9.2.3.4. Strategic initiatives
9.2.4. Thermo Fisher Scientific, Inc.
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Product benchmarking
9.2.4.4. Strategic initiatives
9.2.5. F. Hoffmann-La Roche Ltd.
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Product benchmarking
9.2.5.4. Strategic initiatives
9.2.6. ARUP Laboratories
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Product benchmarking
9.2.6.4. Strategic initiatives
9.2.7. Abbott
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Product benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Myriad Genetics, Inc.
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Product benchmarking
9.2.8.4. Strategic initiatives
9.2.9. bioMérieux SA
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Product benchmarking
9.2.9.4. Strategic initiatives
9.2.10. Invivoscribe, Inc.
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Product benchmarking
9.2.10.4. Strategic initiatives

List of Tables

Table 1 List of abbreviation
Table 2 North America oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 3 North America oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 4 North America oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 5 North America oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 6 North America oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
Table 7 U.S. oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 8 U.S. oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 9 U.S. oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 10 U.S. oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 11 Canada oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 12 Canada oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 13 Canada oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 14 Canada oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 15 Europe oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 16 Europe oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 17 Europe oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 18 Europe oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 19 Europe oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
Table 20 Germany oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 21 Germany oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 22 Germany oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 23 Germany oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 24 UK oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 25 UK oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 26 UK oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 27 UK oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 28 France oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 29 France oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 30 France oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 31 France oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 32 Italy oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 33 Italy oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 34 Italy oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 35 Italy oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 36 Spain oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 37 Spain oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 38 Spain oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 39 Spain oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 40 Denmark oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 41 Denmark oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 42 Denmark oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 43 Denmark oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 44 Sweden oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 45 Sweden oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 46 Sweden oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 47 Sweden oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 48 Norway oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 49 Norway oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 50 Norway oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 51 Norway oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 52 Asia Pacific oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 53 Asia Pacific oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 54 Asia Pacific oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 55 Asia Pacific oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 56 Asia Pacific oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
Table 57 Japan oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 58 Japan oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 59 Japan oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 60 Japan oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 61 China oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 62 China oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 63 China oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 64 China oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 65 India oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 66 India oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 67 India oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 68 India oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 69 Australia oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 70 Australia oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 71 Australia oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 72 Australia oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 73 Thailand oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 74 Thailand oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 75 Thailand oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 76 Thailand oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 77 South Korea oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 78 South Korea oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 79 South Korea oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 80 South Korea oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 81 Latin America oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 82 Latin America oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 83 Latin America oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 84 Latin America oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 85 Latin America oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
Table 86 Brazil oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 87 Brazil oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 88 Brazil oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 89 Brazil oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 90 Mexico oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 91 Mexico oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 92 Mexico oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 93 Mexico oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 94 Argentina oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 95 Argentina oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 96 Argentina oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 97 Argentina oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 98 Middle East and Africa oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 99 Middle East and Africa oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 100 Middle East and Africa oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 101 Middle East and Africa oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 102 Middle East and Africa oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
Table 103 South Africa oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 104 South Africa oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 105 South Africa oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 106 South Africa oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 110 Saudi Arabia oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 111 UAE oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 112 UAE oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 113 UAE oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 114 UAE oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 115 Kuwait oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 116 Kuwait oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 117 Kuwait oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 118 Kuwait oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
보고서 이미지

※본 조사보고서 [세계의 종양학 동반 진단 시장 (2023-2030) : 제품 및 서비스별, 기술별 (IHC, NGS), 질환별 (유방암, 백혈병), 용도별, 지역별] (코드 : GRV23NOV178) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [세계의 종양학 동반 진단 시장 (2023-2030) : 제품 및 서비스별, 기술별 (IHC, NGS), 질환별 (유방암, 백혈병), 용도별, 지역별] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!